The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together colleagues from all over the world. The Scientific Programme is built by the ECCMID Programme Committee (EPC), an independent group of experts representing all disciplines related to Clinical Microbiology, Infectious Diseases, Infection Control and Prevention and Public Health. The event brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000. The Programme Committee has developed a comprehensive scientific and educational programme incorporating Keynote Lectures and Oral Sessions, as well as Educational Workshops, Open Forums, Meet-The-Expert Sessions and a wide range of Scientific Symposia. The number of submitted abstracts has risen to over 5,000, of which roughly 70% are accepted for oral or poster presentation.

Below are the titles of the fungal posters that were presented at ECCMID 2023:

• Rezafungin and caspofungin treatment response in candidaemia/invasive candidiasis by baseline Candida species: analysis of pooled Phase 2 and Phase 3 results
• Repurposing the natural compounds to target Candida auris: silver-cellulose nanoparticles
•  Recurrence in the patients with COVID-19 associated mucormycosis
• Multiple Candida strains causing oral infection in COVID-19 patients under corticosteroids and antibiotic therapy
• Genetic heterogeneity of Italian Candida auris isolates from a prolonged outbreak setting: a genomics-informed study
• Open-label study to evaluate the efficacy and safety of SCY-078 (Ibrexafungerp) in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment (FURI)
• Impact of susceptibility testing method on the detection of amphotericin B resistance among Candida auris clinical isolates
• Efficacy of isavuconazole in a Galleria mellonella model of experimental mucormycosis
• Real-time PCR for Pneumocystis jirovecii pneumonia (PJP): prognostic value in non-HIV immunocompromised patients
• International, multi-centre pharmacokinetic study for screening antifungal exposure in intensive care units: the SAFE-ICU Study, fluconazole
• Invasive fungal infections (IFI) in children with acute leukaemia: results of 10 years of experience in a reference centre
• The impactful activity of nanoemulsion loaded with micafungin against Candida auris infection: in vitro and in vivo assays
• Co-encapsulation of Micafungin and Amphotericin B in nanoemulsion against Candida auris infection
• Emerging echinocandin resistance in Candida parapsilosis triggered by a novel mutation(S656P) in FKS1 Hot Spot 1 region
• One Health approach to resistance of Aspergillus fumigatus to azoles in Hauts-de-France
• Candida auris is not associated with a higher mortality in critically patients with candidemia
• Could PITT score predict mortality in Candida bloodstream infection? A retrospective cohort study
• Predictors of adequate empirical therapy in patients with candidemia
• Risk factors associated with COVID-19 associated pulmonary aspergillosis: a systematic review and meta-analysis
• Cryptococcal infection in renal transplant recipients: a three-decade experience
• An evaluation to assess the clinical performance of a Mucorales IVD real-time PCR kit
• Performance evaluation of Eazyplex Candida auris for detection of C.auris colonisation in intensive care unit
• The urgent need for improvement in diagnostic capacities for fungal infections in healthcare programmes dedicated to PLWH attention in Mexico
• Candida auris: epidemiologic surveillance and changes after the introduction of new management strategies in an intensive care unit of Ospedale Policlinico San Martino IRCCS, Liguria, Italy
• Changing in the epidemiology of candidemia between the pre- and post-COVID-19 period: a multicentre retrospective study
• Clinical characteristics and outcome of patients with candidemia: an observational study from the University Hospital of Pisa
• Pneumocystis jirovecii pneumonia: a changing epidemiology
• Molecular characterisation of Candida auris outbreak isolates in Qatar from COVID-19 patients reveals the emergence of isolates resistant to three classes of antifungal drugs
• Ophthalmologic examination and echocardiography should be the components of candidemia bundle
• A repertoire of clinical moulds
• Fast and accurate identification of Sporothrix brasiliensis using the MALDI-TOF MS methodology
• Current epidemiology of invasive aspergillosis in neutropaenic and non-neutropaenic patients at a university hospital
• High specificity of Aspergillus galactomannan lateral flow for the diagnosis of invasive aspergillosis in a Brazilian referral centre
• Circulatory inflammatory proteins as early diagnostic biomarkers for the development of invasive fungal infections in at-risk patients
• Hypoxia inducible factor 1-alpha governs the invasion of airway epithelial cells by Mucorales
• Fungal bloodstream infection among haematology-oncology and intensive care unit patients in a Greek children's tertiary hospital, during 2000-2022
• Invasive fungal infections in hospitalised children at a tertiary care hospital in New Delhi
• Evaluation of a Histoplasma urine lateral flow device for the diagnosis of proven/probable histoplasmosis
• Evaluation of diagnostic methods and epidemiology of Pneumocystis jirovecii pneumonia: a five-years retrospective study
• A novel protocol design to study the efficacy and safety of oral ibrexafungerp as step-down therapy following intravenous (IV) echinocandin for the treatment of invasive candidiasis (MARIO): developing a paradigm shift to IV and oral anti-cell wall therapy
• Oral ibrexafungerp FURI Study: outcomes in subjects with intra-abdominal candidiasis
• Evolution of Candida glabrata resistance to azoles and echinocandins in two French tertiary hospitals
• Evaluating the in vitro efficacy of ibrexafungerp (SCY-078) against isolates from clinical trial involving patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment (FURI)
• Evaluate the effect of ibrexafungerp alone and in combination with amphotericin B or posaconazole against Mucor strains using time kill kinetics and scanning electron microscopy
• Endemic systemic mycoses in Italy: a systematic review of literature
• Performance of FungiXpert® Aspergillus Galactomannan Detection Kit (CLIA) on bronchoalveolar lavage fluid (BALF)
• Impact of clinical characteristics and race on the pharmacokinetics of posaconazole in patients
• Antifungal susceptibility testing of Candida species: a comparative study of disc diffusion, MIC test strips and broth microdilution methods
• Engineering CAR NK cells to treat invasive pulmonary aspergillosis
• Assessment of viral and invasive aspergillosis co-infections: seven-years cohort in a tertiary care hospital in Madrid, Spain
• Proteomic profiling of the response to 5-fluorocytosine of Cryptococcus neoformans
• Do face masks prevent the early acquisition of Aspergillus sp. and other filamentous fungi in lung transplant recipients? An observational study
• Pulmonary inflammatory response to the exposure to Aspergillus fumigatus spores in a murine model of chronic obstructive pulmonary disease
• Treatment outcomes in candidaemia and/or invasive candidiasis among patients receiving rezafungin or caspofungin while the fungal culture was still positive
• Investigating the effect of linoleic acid conjugated with chitosan-coated with zinc oxide nanoparticles in inhibiting the expression of MDR and CDR genes in Candida albicans by real-time PCR technique
• Serum beta-D-glucan in the assessment of invasive fungal infections in patients with liver cirrhosis
• Pilocarpine interferes with apoptotic pathways in Candida albicans
• Short tandem repeat genotyping reveals high relatedness between Dutch flucytosine resistant Candida tropicalis isolates
• Comparison of methods used for molecular typing of Candida parapsilosis strains: is the oldest method still the best?
• Rapid detection of galactomannan in serum using label-free surface-enhanced Raman scattering (SERS) spectroscopy: a pilot study
• The relationship between time to positivity for Candida species and clinical outcomes in patients with candidaemia
• Paracoccidioidomycosis with central nervous system involvement, experience from an endemic area in Argentina
• Liposomal amphotericin b plasma concentration and adverse events in immunocompromised children undegoing antifungal prophylaxis
• Rapid species-level identification of Aspergillus via label-free surface-enhanced Raman scattering (SERS) spectroscopy: a pilot study
• Mutations in PDR1 lead to overexpression of drug efflux pumps CDR1, CDR2 and SNQ2 in Candida glabrata
• Antifungal prophylaxis and invasive fungal disease in children with acute leukaemia: a multicentre Australian study 2017-2020
• EUCAST-obtained MIC of azoles and amphotericin B against Aspergillus fumigatus sensu stricto: spectrophotometric readings visual inspections showed high agreement
• Seven-years prospective cohort of invasive aspergillosis in a tertiary care hospital in Madrid (Spain): we still need better classification criteria.
• EUCAST-obtained olorofim MICs against non-fumigatus Aspergillus clinical isolates: high agreements between visual inspections and spectrophotometric readings
• Safety outcomes with rezafungin and caspofungin in the treatment of candidaemia and/or invasive candidiasis: phase 3 data from the ReSTORE trial
• In vitro feasibility studies for successful in vivo application of microdialysis: a workflow for posaconazole
• Epidemiology of fungaemia and antifungal resistance during the COVID-19 pandemic in a tertiary care hospital in Madrid (Spain): a shift towards a higher number of C. albicans cases alongside steady low antifungal resistance
• Evaluation of lateral flow device in bronchoalveolar lavage fluids for diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA)
• Cryptococcosis in patients with cancer: clinic and epidemiology
• Performance of three automated nucleic acid extraction systems for bronchoalveolar lavage fluid (BALF) following Fungal PCR Initiative (FPCRI) recommendations
• Comparative pharmacodynamics of liposomal amphotericin B against Candida isolates in an in vitro PK/PD model
• In vitro activity of amphotericin B and azoles against non-fumigatus Aspergillus clinical isolates collected in a multi-centre study conducted in Spain: low rate of resistance to amphotericin B and azoles
• Rapid identification of clinically relevant Candida species from positive blood cultures using a new molecular assay
• Impact of Candida colonisation in patients with candidaemia admitted in a tertiary care hospital in Madrid
• Azole resistance in clinical Aspergillus fumigatus in Spain: the presence of the TR34-L98H substitution is confirmed in the 2022 survey
• Baseline risk factors for mortality in Candidaemia: the role of Candida tropicalis and rare Candida species
• Multi-centre evaluation of low inoculum for antifungal susceptibility of Aspergillus fumigatus to echinocandins with the EUCAST E.Def 9.4
• Etest-based wild-type upper limits for rare Candida spp.
• C. parapsilosis microsatellite genotyping: are all available markers equally discriminative?
• Understanding the dynamics of pulmonary colonisation with Pneumocystis jirovecii: usefulness of multilocus sequence typing
• Virulence, antifungal susceptibility and pathogenicity of medically important Candida albicans from pigeon droppings
• Liposomal amphotericin B pharmacodynamics against Candida auris isolates in an in vitro pharmacokinetic/pharmacodynamic dilution model
• Looking for fungi in cystic fibrosis airway after new modulator therapy: are they leaving?
• Candida auris bacteraemia in COVID patients: susceptibility and patients’ outcome
• Update on MIC-elevations of FKS mutant Candida isolates: direct translation to echinocandin susceptibility is challenging and supports including two echinocandins to detect non-WT isolates
• Evaluation of the performance of ?-D-glucan for invasive fungal infection
• Pulmonary co-infections by Pneumocystis jirovecii and Herpesviridae: a seven-year retrospective study
• Evidence of genotypic diversity among Candida auris isolates by microsatellite typing in Russia
• Evaluation of a novel antigen ELISA for the diagnostics of invasive pulmonary aspergillosis
• Pneumocystis jirovecii pneumonia in HIV vs non-HIV patients: which are the differences?
• Antimycotic and antifungal prescribing patterns worldwide: results from the Global Point Prevalence Survey on Antimicrobial Consumption and Resistance
• Clinical characteristics and correlation between epidemiological cut-off values (ECV) and mortality in patients with cryptococcosis
• Fungal implant-associated infections in trauma and orthopaedic surgery procedures in Slovenia: a 10-year database study
• Breakthrough invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients on posaconazole prophylaxis
• Anatomical compartmentalisation of echinocandin-resistant Candida glabrata: whole genome sequencing not only confirms the fact but also unveils the presence of resistant subpopulations
• Detection of Y132F ERG11p substitution in fluconazole-resistant Candida parapsilosis isolates by means of conventional and TaqMan® SNP genotyping targeted-mutation PCR
• Iron regulatory pathways differentially expressed during Madurella mycetomatis grain development in Galleria mellonella
• Can daily bathing with 4% chlorhexidine + daily chlorhexidine wipe for one week be effective in decolonising Candida auris colonisation?
• ERG11p mutations and profile of azole resistance in fluconazole-resistant C. parapsilosis genotypes affecting hospitals located in Spain and Italy
• Commercial real time PCR for rapid diagnosis of dermatophytosis
• Antifungal susceptibility pattern of Candida auris strains: Analysis of 40 clinical strains in a tertiary care educational hospital
• Prospective evaluation of septic shock patients with culture-proven Candida spp in a tertiary care educational university hospital: a series of 64 cases
• Retrospective study of a cohort of patients with Pneumocystis jirovecii pneumonia admitted at ""Policlinico Tor Vergata"" between 2017 and 2021
• New emerging dermatophyte resistant to terbinafine: Trichophyton indotineae identification by MALDI-TOF MS
• COVID-19 associated rhino-orbital-cerebral mucormycosis: clinical features, antifungal susceptibility, management and outcome in a tertiary hospital in Iran
• Epidemiology of clinically significant Aspergillus species in a tertiary hospital in China
• Clinical outcomes of Candida auris management: a retrospective study
• Characterising Candida growth phases and drug susceptibilities using ATR-FTIR spectroscopy and machine learning techniques
• Emergence of antifungal resistant sub-clades in global predominant phylogenetic population of Candida albicans
• The combination of hapE and hmg1 mutations accounts for triazole drug resistance in an A. fumigatus clinical isolate carrying no mutations in cyp51A
• Molecular characterisation and in vitro antifungal susceptibility of Mucorales causing COVID-associated mucormycosis (CAM)
• Differences in liposomal amphotericin B accumulation in the lungs of normal and obese ICR mice with pulmonary aspergillosis
• The influence of CRRT on (1,3)-beta-D-glucan levels in critically ill patients
• Equivalent concentration of isavuconazole administered via enteral feeding tube compared to IV or oral formulation in patients treated for invasive pulmonary aspergillosis
• Current epidemiology of Pneumocystis jirovecii pneumonia in a university hospital
• Alarming change in epidemiology of ICU-acquired candidaemia in a Greek teaching hospital during the COVID-19 era: worrisome emergence of Candida auris
• Applying data science to measure incidence of invasive fungal infection in acute leukaemia highlights diagnostic uncertainty
• COVID-19-associated pulmonary aspergillosis: species distribution and susceptibility profiles
• Correlating clinical manifestations, endoscopic grade, and pathological data in esophageal candidiasis in contemporary cancer patients: a single institution experience
• Molecular detection of dermatophytes: comparison of two diagnostic methods
• Changing epidemiology in invasive mold infections towards non-Aspergillus species: a single centre experience
• Candida spp. infections of osteoarticular prostheses (IPOAs): a bicentric study of 17 cases
• Cardiac involvement in mucormycosis
• New insights in the pathogenesis of recurrent vulvovaginal candidiasis: a prospective clinical study
• Role of source control in critically ill candidaemic patients: a multi-centre retrospective study
• Evolving epidemiology of Candida bloodstream infections in a Greek university tertiary hospital
• Feasibility of EORTC-MSG definitions for invasive fungal disease in patients with haematological malignancies in real life: a SEIFEM study (Sorveglianza Epidemiologica Infezioni Nelle Emopatie)
• Clinical factors associated with invasive aspergillosis mortality: a global research network study, 2022
• Impact of targeted posaconazole prophylaxis in heart transplant recipients during an outbreak of early invasive aspergillosis
• Efficacy assessment of SF001, a third generation polyene antifungal, in the neutropenic mouse model of pulmonary mucormycosis
• Comparison of three beta-glucan tests for the diagnosis of invasive candidiasis in intensive care units
• Mycological diagnosis in Spain: identification, sensitivity testing and non-care activity: a GEMICOMED-SEIMC survey
• Mycological diagnosis in Spain, technical capabilities: a GEMICOMED-SEIMC survey
• In vivo efficacy of the novel azole compounds (ATTAF-1 and ATTAF-2) against invasive candidiasis in a murine model
• Invasive fungal disease in acute myeloid leukaemia patients, a 5 year review in the Mater Misercordiae University Hospital, Dublin, Ireland
• Distinguishing invasive from chronic pulmonary infections and aspergillosis from mucormycosis: host pentraxin 3 and fungal siderophores in bronchoalveolar lavage fluids
• Clonal spreading of fluconazole-resistant C. parapsilosis causing invasive infections in patients admitted to a referral hospital located in Burgos, Northern Spain
• Multicentre epidemiological study of Yarrowia lipolytica in China from 2010 to 2020
• Azole resistance in Aspergillus fumigatus: data from the Czech surveillance study, 2019–2021
• Falciformispora senegalensis grain model in Galleria mellonella larvae
• Clonal dissemination of antifungal-resistant Candida haemulonii in China: implication from population genomics
• Antifungal susceptibility profiles and drug resistance mechanisms of clinical Candida duobushaemulonii isolates from China
• ?-D-Glucan assay in the cerebrospinal fluid for the diagnosis of non-cryptococcal fungal infection of the central nervous system: a retrospective multicentric analysis and a comprehensive review of the literature
• Potential for weekly administration of echinocandin outpatient parenteral antimicrobial therapy (OPAT): observations and analysis of echinocandin use in the OPAT setting
• Fungal translocation measured by serum 1,3-ß-D-glucan is associated with severity and outcome of liver cirrhosis: a pilot study
• A multi-centre analysis of isavuconazole for treatment of probable/proven invasive aspergillosis and mucormycosis
• Staphylococcus aureus ClpP protein synergies with echinocandins against drug-resistant Candida species
• Identification and evaluation of antifungal susceptibility of rare opportunist yeasts
• Chronic pulmonary aspergillosis in patients admitted for lungs diseases in Yaoundé, Cameroon
• High prevalence of invasive candidiasis in neonates in Southeast Asia and the Pacific
• Comparative evaluation of the diagnostic performance of two Aspergillus antigen ELISAs
• Corticosteroids as a risk factor and outcome modulator in non-HIV, non-transplant patients with Cryptococcal meningoencephalitis
• A lateral flow immunoassay for the rapid identification of Candida auris
• Inhibitory effects of vaginal lactobacilli on Candida albicans biofilm development, and epithelial cell adhesion
• Isolation, identification, determination of drug sensitivity and evaluation of expression of MDR1 and CDR1 genes in Candida albicans obtained from vulvovaginal candidiasis
• A novel multiplex PCR assay for rapid detection and typing of Candida using melting curve analysis
• Safety and efficacy of isavuconazole for the treatment of invasive fungal infections: a real-life experience
• Monitorisation with microbiological markers (PCR, GM and BDG) during nebulized liposomal amphotericin B (NLAB) therapy in invasive pulmonary aspergillosis (IPA): a pilot clinical trial (NAIFI)
• Efficacy of oteseconazole for the treatment of recurrent vulvovaginal candidiasis: a systematic review and meta-analysis
• Screening antifungal profile of clinical Candida isolates from patients in Ivorian intensive care units in 2022
• Epidemiology, and genetic characterisation of Candida orthopsilosis by microsatellite typing in China
• Species diversity and antifungal susceptibility patterns of 385 Aspergillus section Nigri isolates from clinical specimens in the United States
• Review of guideline observance in relation to infectious diseases consultation for adult patients with candidemia living in Calgary Alberta, Canada (2010 – 2018)
• Invasive aspergillosis diagnosis: comparison of real-time PCR, galactomannan antigen detection and culture in a tertiary care hospital of northern Italy
• A novel rapid test for MycoMDX Mucor PCR assay
• Aspergillus galactomannan lateral flow assay with digital reader for the diagnosis of invasive aspergillosis
• Application of PCR-fluorescence probe method in molecular diagnosis of Talaromyces marneffei infection
• A novel multiplex PCR assay with melting curve analysis for rapid detection of Aspergillus species and azole resistance
• Examination of the fungus (1-3)-?-D-glucan assay (chemiluminescence) in serum for diagnosing invasive fungal disease
• Assessment of ISZ efficacy and tolerance in a two years prospective real-life study
• Risk factors for 30-day mortality revealed by a predictive model of Candida parapsilosis candidemia patients
• Distribution of azole-resistant Aspergillus fumigatus and detection of azole-resistance related to the cyp51A mutation in hospital environmental samples: a nationwide surveillance from Iran
• Laboratory capacities to diagnose and treat invasive fungal infections in Italy: local results from an ECMM survey
• Evaluation of clinical and epidemiological characteristics of patients of candidemia with and without COVID-19
• In vitro activity of manogepix and comparators against 488 infrequently encountered yeast and mould isolates from the SENTRY surveillance programmme (2017-2022)
• Trends on the activity of mould-active agents against Aspergillus fumigatus clinical isolates with and without Cyp51 alterations from Europe and North America (2017–2021)
• Survey of fungal diagnostic stewardship practices in an Indian hospitals
• Rezafungin activity against Candidemia isolates collected from European medical centres (2019–2021)
• Rezafungin activity against Candida spp. and Aspergillus spp. isolates causing invasive infections in European medical centres (2019–2021)
• Epidemiology of invasive fungal infection in patients receiving Bruton`s tyrosine kinase inhibitor treatment: a multicentre cohort experience
• A polymorphism in IL1B is associated with immune reconstitution inflammatory syndrome due to chronic disseminated candidiasis
• The treatment of fungal infections in the Republic of Ireland using outpatient parental antifungal therapy: a retrospective review 2013-2021
• Antifungal effectiveness of mucoadhesive containing chlorhexidine complexed with ?-cyclodextrin as an alternative therapy for denture stomatitis
• Dermatology mycology diagnostics in Ireland: a national deficits of international relevance
• Epidemiology of dermatomycoses and onychomycoses in Ireland (2001 to 2020): a single-institution review
• In vitro combination of terbinafine with ketoconazole against terbinafine-resistant Aspergillus species isolated from otomycosis
• The role of bile microbiome in pancreatic and extra pancreatic cancer patients
• Effect of dexamethasone on the incidence and outcome of COVID-19 associated pulmonary aspergillosis (CAPA) in critically ill patients: a single-centre experience
• Development of a case-fatality prognostic score for HIV-associated histoplasmosis
• The mortality rate of non-HIV infected patients with cryptococcosis: the real-world data from one referral centre in northeastern Thailand
• Laboratory capacities to diagnose and treat invasive fungal infections in Nordic countries: results from an NSMM and ECMM survey
• In vitro synergistic efficacy of nystatin combined with geraniol against Candida biofilm on acrylic resin
• Evaluation of clinical features and risk factors of invasive mould infections associated with COVID-19: a single-centre experience
• Laboratory­ capacities­ to­ diagnose­ and­ treat­ invasive­ fungal ­infections ­in ­Austria, ­Germany­ and ­Switzerland